A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries. Issue 12 (December 2022)

Record Type:: Journal Article
Title:: A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States: The Cost-Effectiveness of Dapagliflozin in Three European Countries. Issue 12 (December 2022)
Main Title:: A Blueprint for Assessing Affordability of SGLT2 Inhibitors in the United States
Authors:: Khine, Annika
Lin, Eugene
Abstract:
Is Part Of:: Clinical journal of the American Society of Nephrology. Volume 17:Issue 12(2022)
Journal:: Clinical journal of the American Society of Nephrology
Issue:: Volume 17:Issue 12(2022)
Issue Display:: Volume 17, Issue 12 (2022)
Year:: 2022
Volume:: 17
Issue:: 12
Issue Sort Value:: 2022-0017-0012-0000
Page Start:: 1707
Page End:: 1709
Publication Date:: 2022-12
Subjects:: chronic kidney disease -- economic analysis -- progression of chronic renal failure
DOI:: 10.2215/CJN.09900822 ↗
Languages:: English
ISSNs:: 1555-9041
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library HMNTS - ELD Digital store
Ingest File:: 26454.xml